STUDY OBJECTIVES: The study aimed to document the neurobehavioral outcomes of patients referred to and treated by a sleep medicine service for moderate to severe obstructive sleep apnea (OSA). In particular, we aimed to establish the proportion of patients who, while appearing to have optimal continuous positive airway pressure (CPAP) adherence, did not normalize their daytime sleepiness or neurocognitive function after 3 months of CPAP therapy despite effective control of OSA. DESIGN: Multicenter clinical-effectiveness study. SETTING:Three academic sleep centers in Australia. PARTICIPANTS: Patients referred to a sleep medicine service with moderate to severe OSA (n = 174). INTERVENTION: CPAP. MEASUREMENTS AND RESULTS: Participants were assessed pretreatment and again after 3 months of CPAP therapy. At the beginning and at the conclusion of the trial, participants completed a day of testing that included measures of objective and subjective daytime sleepiness, neurocognitive function, and quality of life. In patients with symptomatic moderate to severe OSA (i.e., apnea-hypopnea index > 30/h), we found a treatment dose-response effect for CPAP in terms of Epworth Sleepiness Scale scores (P < 0.001). Several key indexes of neurobehavior (e.g., Functional Outcomes of Sleep Questionnaire, Epworth Sleepiness Scale) currently used to assess treatment response failed to normalize in a substantial group of patients after 3 months of CPAP treatment, even in those who were maximally compliant with treatment. Forty percent of patients in this trial had an abnormal Epworth Sleepiness Scale score at the conclusion of the trial. In addition, we showed no dose-response effect with the Maintenance of Wakefulness Test, raising doubts as to the clinical utility of the Maintenance of Wakefulness Test in assessing treatment response to CPAP in patients with OSA. CONCLUSIONS: Our study suggests that a greater percentage of patients achieve normal functioning with longer nightly CPAP duration of use, but a substantial proportion of patients will not normalize neurobehavioral responses despite seemingly adequate CPAP use. It is thus crucial to adequately assess patients after CPAP therapy and seek alternate etiologies and treatments for any residual abnormalities.
RCT Entities:
STUDY OBJECTIVES: The study aimed to document the neurobehavioral outcomes of patients referred to and treated by a sleep medicine service for moderate to severe obstructive sleep apnea (OSA). In particular, we aimed to establish the proportion of patients who, while appearing to have optimal continuous positive airway pressure (CPAP) adherence, did not normalize their daytime sleepiness or neurocognitive function after 3 months of CPAP therapy despite effective control of OSA. DESIGN: Multicenter clinical-effectiveness study. SETTING: Three academic sleep centers in Australia. PARTICIPANTS: Patients referred to a sleep medicine service with moderate to severe OSA (n = 174). INTERVENTION: CPAP. MEASUREMENTS AND RESULTS:Participants were assessed pretreatment and again after 3 months of CPAP therapy. At the beginning and at the conclusion of the trial, participants completed a day of testing that included measures of objective and subjective daytime sleepiness, neurocognitive function, and quality of life. In patients with symptomatic moderate to severe OSA (i.e., apnea-hypopnea index > 30/h), we found a treatment dose-response effect for CPAP in terms of Epworth Sleepiness Scale scores (P < 0.001). Several key indexes of neurobehavior (e.g., Functional Outcomes of Sleep Questionnaire, Epworth Sleepiness Scale) currently used to assess treatment response failed to normalize in a substantial group of patients after 3 months of CPAP treatment, even in those who were maximally compliant with treatment. Forty percent of patients in this trial had an abnormal Epworth Sleepiness Scale score at the conclusion of the trial. In addition, we showed no dose-response effect with the Maintenance of Wakefulness Test, raising doubts as to the clinical utility of the Maintenance of Wakefulness Test in assessing treatment response to CPAP in patients with OSA. CONCLUSIONS: Our study suggests that a greater percentage of patients achieve normal functioning with longer nightly CPAP duration of use, but a substantial proportion of patients will not normalize neurobehavioral responses despite seemingly adequate CPAP use. It is thus crucial to adequately assess patients after CPAP therapy and seek alternate etiologies and treatments for any residual abnormalities.
Entities:
Keywords:
OSA; neurobehavioral function; neurocognitive function
Authors: Paul M Macey; Luke A Henderson; Katherine E Macey; Jeffry R Alger; Robert C Frysinger; Mary A Woo; Rebecca K Harper; Frisca L Yan-Go; Ronald M Harper Journal: Am J Respir Crit Care Med Date: 2002-11-15 Impact factor: 21.405
Authors: Mary J Morrell; Donald W McRobbie; Rebecca A Quest; Andrew R C Cummin; Ramesh Ghiassi; Douglas R Corfield Journal: Sleep Med Date: 2003-09 Impact factor: 3.492
Authors: Clifford A Massie; Nigel McArdle; Robert W Hart; Wolfgang W Schmidt-Nowara; Alan Lankford; David W Hudgel; Nancy Gordon; Neil J Douglas Journal: Am J Respir Crit Care Med Date: 2002-10-04 Impact factor: 21.405
Authors: Nick A Antic; Catherine Buchan; Adrian Esterman; Michael Hensley; Matthew T Naughton; Sharn Rowland; Bernadette Williamson; Samantha Windler; Simon Eckermann; R Doug McEvoy Journal: Am J Respir Crit Care Med Date: 2009-01-08 Impact factor: 21.405
Authors: Ramon Farre; Miguel Angel Martínez-García; Francisco Campos-Rodriguez; Josep M Montserrat Journal: Sleep Date: 2015-12-01 Impact factor: 5.849
Authors: Richard J Schwab; Safwan M Badr; Lawrence J Epstein; Peter C Gay; David Gozal; Malcolm Kohler; Patrick Lévy; Atul Malhotra; Barbara A Phillips; Ilene M Rosen; Kingman P Strohl; Patrick J Strollo; Edward M Weaver; Terri E Weaver Journal: Am J Respir Crit Care Med Date: 2013-09-01 Impact factor: 21.405
Authors: Anna E Mullins; Korey Kam; Ankit Parekh; Omonigho M Bubu; Ricardo S Osorio; Andrew W Varga Journal: Neurobiol Dis Date: 2020-08-27 Impact factor: 5.996
Authors: Fernanda R Almeida; Alan Mulgrew; Najib Ayas; Hiroko Tsuda; Alan A Lowe; Nurit Fox; Sandra Harrison; John A Fleetham Journal: J Clin Sleep Med Date: 2013-04-15 Impact factor: 4.062
Authors: Yuan Feng; David Maislin; Brendan T Keenan; Thorarinn Gislason; Erna S Arnardottir; Bryndis Benediktsdottir; Julio A Chirinos; Raymond R Townsend; Bethany Staley; Francis M Pack; Andrea Sifferman; Allan I Pack; Samuel T Kuna Journal: J Clin Sleep Med Date: 2018-10-15 Impact factor: 4.062